Brent Vaughan Email

CEO . Cognito Therapeutics

Current Roles

Employees:
72
Revenue:
$7.5M
About
Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer’s disease and expects to start pivotal studies in 2022. The company’s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.
Cognito Therapeutics Address
1218 Massachusetts Ave
Cambridge, MA
Cognito Therapeutics Email

Past Companies

Kuzani Pharmaceuticals, Inc.Board Member
Kuzani Pharmaceuticals, Inc.CEO & Founder
Cognito Therapeutics, Inc.Chief Executive Officer

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.